Traws Pharma Secures $60M Financing for Flu Challenge Study and Extends Runway to Q1 2027
Traws Pharma (NASDAQ:TRAW) has secured $60 million in private financing, which will support its flu challenge study this summer and extend its financial runway into Q1 2027. The funding is intended to advance the company's flu program and support ongoing research.
Topics: capital raising financing pharmaceuticals Traws Pharma